EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resistant Hypertension in Adults in the Cardio–Renal–Metabolic Era: A Contemporary Position Statement

Silvia Palomo-Piñon, Luis Alcocer, Humberto Álvarez-López, José M Enciso-Muñoz, Héctor Galván-Oseguera, Adolfo Chávez-Mendoza, Enrique Díaz-Díaz, Ernesto Cardona-Muñoz, Martin Rosas-Peralta

Annals of Clinical Hypertension · 23.07.2026 · 22-30

DOI: 10.29328/journal.ach.1001044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Hypertension, online erschienen am 23.07.2026. Verfasst von Silvia Palomo-Piñon und 8 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant hypertension (RH) remains one of the most challenging clinical scenarios in cardiovascular medicine due to its strong association with target-organ damage, chronic kidney disease (CKD), heart failure, atrial fibrillation, stroke, and premature mortality. Contemporary evidence has transformed the understanding of RH from a simple state of uncontrolled blood pressure into one of a phenotype of a complex cardio–renal–metabolic syndrome characterized by persistent neurohormonal activation, sodium retention, endothelial dysfunction, sympathetic overactivity, obesity, inflammation, and relative aldosterone excess. Importantly, a substantial proportion of apparent resistant hypertension represents pseudoresistance caused by poor adherence, suboptimal pharmacologic regimens, white-coat effect, and inaccurate blood pressure measurement. Recent advances in ambulatory blood pressure monitoring (ABPM), precision phenotyping, and mechanistic therapies have reshaped diagnostic and therapeutic strategies. Spironolactone remains the preferred fourth-line therapy following optimized triple treatment, supported by robust evidence from PATHWAY-2. Chlorthalidone has demonstrated efficacy in advanced CKD, whereas sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) provide additional cardio–renal–metabolic benefits. Emerging therapies—including aprocitentan, aldosterone synthase inhibitors such as baxdrostat and lorundrostat, and RNA interference therapies targeting angiotensinogen—represent major advances in difficult-to-control hypertension. Likewise, renal denervation has re-emerged as a promising interventional strategy in carefully selected patients. This Position Statement summarizes current evidence regarding epidemiology, pathophysiology, diagnosis, phenotyping, and treatment of resistant hypertension, proposing a modern management paradigm focused not only on blood pressure control but also on comprehensive cardio–renal–metabolic risk reduction.

Zitieren

APA

Palomo-Piñon, S., Alcocer, L., Álvarez-López, H., Enciso-Muñoz, J. M., Galván-Oseguera, H., Chávez-Mendoza, A., Díaz-Díaz, E., Cardona-Muñoz, E., & Rosas-Peralta, M. (2026). Resistant Hypertension in Adults in the Cardio–Renal–Metabolic Era: A Contemporary Position Statement. Annals of Clinical Hypertension, 22-30. https://doi.org/10.29328/journal.ach.1001044

Vancouver

Palomo-Piñon S, Alcocer L, Álvarez-López H, Enciso-Muñoz JM, Galván-Oseguera H, Chávez-Mendoza A, et al. Resistant Hypertension in Adults in the Cardio–Renal–Metabolic Era: A Contemporary Position Statement. Annals of Clinical Hypertension. 2026:22-30. doi:10.29328/journal.ach.1001044

BibTeX
@article{PalomoPion2026,
  author = {Palomo-Piñon, Silvia and Alcocer, Luis and Álvarez-López, Humberto and Enciso-Muñoz, José M and Galván-Oseguera, Héctor and Chávez-Mendoza, Adolfo and Díaz-Díaz, Enrique and Cardona-Muñoz, Ernesto and Rosas-Peralta, Martin},
  title = {Resistant Hypertension in Adults in the Cardio–Renal–Metabolic Era: A Contemporary Position Statement},
  journal = {Annals of Clinical Hypertension},
  year = {2026},
  pages = {22--30},
  doi = {10.29328/journal.ach.1001044}
}
Kostenlos starten →